Dyadic International, Inc. (DYAI)
Key Executives
| Name | Title | Pay | Exercised | Year Born |
|---|---|---|---|---|
|
Mr. Mark A. Emalfarb
|
Founder, CEO & Director | 812.89k | -- | 1956 |
|
Mr. Joseph P. Hazelton
|
President & COO | 383.03k | -- | 1976 |
|
Ms. Ping Wang Rawson CPA, M.B.A.
|
CFO & Principal Accounting Officer | 341.08k | -- | 1975 |
|
Ms. Ana Gómez Rodriguez
|
Secretary of the Board | -- | -- | -- |
Dyadic International, Inc.
- Sector:
- Healthcare
- Industry: Biotechnology
- Full Time Employees:
- 5
Description
Dyadic International, Inc., together with its subsidiaries, a biotechnology platform company, develops, manufactures, and commercializes proteins and enzymes in the United States. The company offers Dapibus Protein Production Platform, a proprietary expression system designed to produce non-animal proteins and enzymes for non-pharmaceutical markets, including life sciences, food and nutrition, and bio-industrial sector; and C1 Protein Production Platform, a thermophilic fungal platform for large-scale production of proteins. It has a research and development agreement with VTT Technical Research Centre of Finland, Ltd; license agreement with Rubic One Health to develop various livestock vaccines; sub-license agreement with Phibro Animal Health/Abic Biological Laboratories to develop vaccines and treatments for livestock diseases; and collaboration with Scripps Research to evaluate monoclonal antibody and vaccine candidates targeting hantaviruses. Dyadic International, Inc. was founded in 1979 and is headquartered in Jupiter, Florida.
Corporate Governance
Upcoming Events
November 12, 2026 at 9:00 PM UTC
Dyadic International, Inc. Earnings Date
